Axin induces cell death and reduces cell proliferation in astrocytoma by activating the p53 pathway

International Journal of Oncology

Volumn 35, Issue 1, 2009, Pages 25-32

  Zhang, Li Ying ^a   Ye, Jing ^a   Zhang, Feng ^a   Li, Fan Fan ^a   Li, Hang ^a   Gu, Yu ^a   Liu, Fang ^a   Chen, Guang Sheng ^a   Li, Qing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Astrocytoma; Axin; P53; Proliferation

Indexed keywords

AXIN; CYCLIN D1; PROTEIN P21; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ARTICLE; ASTROCYTOMA; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CHILD; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANIMALS; APOPTOSIS; ASTROCYTOMA; BENZOTHIAZOLES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; RATS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIME FACTORS; TOLUENE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 67649417871     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000309     Document Type: Article

References (35)

1. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7: 755-764, 1997.
2. Baeza N, Masuoka J, Kleihues P and Ohgaki H: AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 22: 632-636, 2003.
3. Collins VP: Genetic alterations in gliomas. J Neurooncol 24: 37-38, 1995.
4. Zeng L, Fagotto F, Zhang T, et al: The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90: 181-192, 1997.
5. Kikuchi A: Roles of Axin in the Wnt signalling pathway. Cell Signal 11: 777-788, 1999.
6. Luo W and Lin SC: Axin: a master scaffold for multiple signaling pathways. Neurosignals 13: 99-113, 2004.
7. Luo W, Ng WW, Jin LH, Ye Z, Han J and Lin SC: Axin utilizes distinct regions for competitive MEKK1 and MEKK4 binding and JNK activation. J Biol Chem 278: 37451-37458, 2003.
8. Ikeda S, Kishida M, Matsuura Y, Usui H and Kikuchi A: GSK-3beta-dependent phos-phorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with axin. Oncogene 19: 537-545, 2000.
9. Kishida S, Yomamato H, Ikeda S, Kishida M, Sakamoto I, Koyama S and Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 273: 10823-10826, 1998.
10. Zhang Y, Neo SY, Wang X, Han J and Lin SC: Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J Biol Chem 274: 35247-35254, 1999.
11. Rui Y, Xu Z, Lin S, et al: Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J 23: 4583-4594, 2004.
12. Li Q, Wang X, Wu X, et al: Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res 67: 66-74, 2007.
13. Lin SC and Li Q: Axin bridges Daxx to p53. Cell Res 17: 301-302, 2007.
14. Nakajima M, Fukuchi M, Miyazaki T, Masuda N, Kato H and Kuwano H: Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma. Br J Cancer 88: 1734-1739, 2003.
15. Neo SY, Zhang Y, Yaw LP, Li P and Lin SC: Axin-induced apoptosis depends on the extent of its JNK activation and its ability to down-regulate beta-catenin levels. Biochem Biophys Res Commun 272: 144-150, 2000.
16. Li Q, Zhang XQ, Nie L, et al: Expression of interferon-gamma in human adrenal gland and kidney tumours. Br J Cancer 97: 420-425, 2007.
17. Liu S, Fang X, Hall H, et al: Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci USA 105: 5248-5253, 2008.
18. Zhang LY, Li Q, Chen GS, et al: [Construction of the eukaryotic expression vector pIRES2-EGFP-Axin and its expression in glioma cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 21: 408-410, 2005.
19. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
20. INK4a, cyclin G1, and the proto-oncogene Bax. J Comp Neurol 397: 181-198, 1998.
21. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
22. Ismail IA, Kang KS, Lee HA, Kim JW and Sohn YK: Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol 575: 12-20, 2007.
23. Zhou CX and Gao Y: Frequent genetic alterations and reduced expression of the Axin1 gene in oral squamous cell carcinoma: involvement in tumor progression and metastasis. Oncol Rep 17: 73-79, 2007.
24. Xu HT, Wei Q, Liu Y, et al: Overexpression of axin down-regulates TCF-4 and inhibits the development of lung cancer. Ann Surg Oncol 14: 3251-3259, 2007.
25. Tortosa A, Vinolas N, Villa S, et al: Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97: 1063-1071, 2003.
26. Castellani P, Borsi L, Carnemolla B, et al: Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 161: 1695-1700, 2002.
27. Zolota V, Tsamandas AC, Aroukatos P, et al: Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome. Neuropathology 28: 35-42, 2008.
28. Mao Y, Zhou L, Zhu W, et al: Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci 12: 2252-2259, 2007.
29. Liu C, Li Y, Semenov M, et al: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-847, 2002.
30. Satoh S, Daigo Y, Furukawa Y, et al: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245-250, 2000.
31. Hsu W, Shakya R and Costantini F: Impaired mammary gland and lymphoid development caused by inducible expression of Axin in transgenic mice. J Cell Biol 155: 1055-1064, 2001.
32. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
33. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
34. Adachi S, Jigami T, Yasui T, et al: Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res 64: 8496-8501, 2004.
35. Attardi LD and DePinho RA: Conquering the complexity of p53. Nat Genet 36: 7-8, 2004.